BioInvent International AB (publ) (BINV.ST)
SEK 39.75
(2.45%)
SEK 39.75
(2.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 90.45 Million SEK | -14.74% |
| 2022 | 106.09 Million SEK | 32.08% |
| 2021 | 80.32 Million SEK | 35.82% |
| 2020 | 59.14 Million SEK | 4.35% |
| 2019 | 56.67 Million SEK | 72.9% |
| 2018 | 32.77 Million SEK | -17.69% |
| 2017 | 39.82 Million SEK | -13.17% |
| 2016 | 45.86 Million SEK | 83.5% |
| 2015 | 24.99 Million SEK | 15.28% |
| 2014 | 21.68 Million SEK | -33.15% |
| 2013 | 32.43 Million SEK | -52.94% |
| 2012 | 68.91 Million SEK | 1.64% |
| 2011 | 67.8 Million SEK | 6.21% |
| 2010 | 63.83 Million SEK | -9.59% |
| 2009 | 70.61 Million SEK | 10.11% |
| 2008 | 64.12 Million SEK | 12.74% |
| 2007 | 56.88 Million SEK | 48.99% |
| 2006 | 38.18 Million SEK | -19.36% |
| 2005 | 47.34 Million SEK | 84.02% |
| 2004 | 25.72 Million SEK | -32.7% |
| 2003 | 38.22 Million SEK | -26.71% |
| 2002 | 52.15 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 101.47 Million SEK | 5.72% |
| 2024 Q1 | 95.99 Million SEK | 6.12% |
| 2024 Q3 | 84.38 Million SEK | -16.85% |
| 2023 Q4 | 90.45 Million SEK | 17.82% |
| 2023 Q3 | 76.77 Million SEK | -37.28% |
| 2023 FY | 90.45 Million SEK | -14.74% |
| 2023 Q2 | 122.4 Million SEK | 32.17% |
| 2023 Q1 | 92.6 Million SEK | -12.71% |
| 2022 Q1 | 81.45 Million SEK | 1.41% |
| 2022 Q3 | 70.84 Million SEK | -20.73% |
| 2022 Q4 | 106.09 Million SEK | 49.76% |
| 2022 FY | 106.09 Million SEK | 32.08% |
| 2022 Q2 | 89.36 Million SEK | 9.71% |
| 2021 Q4 | 80.32 Million SEK | 7.55% |
| 2021 FY | 80.32 Million SEK | 35.82% |
| 2021 Q1 | 61.29 Million SEK | 3.64% |
| 2021 Q3 | 74.68 Million SEK | -6.74% |
| 2021 Q2 | 80.08 Million SEK | 30.66% |
| 2020 Q1 | 57.88 Million SEK | 2.13% |
| 2020 FY | 59.14 Million SEK | 4.35% |
| 2020 Q4 | 59.14 Million SEK | 18.9% |
| 2020 Q3 | 49.73 Million SEK | -13.35% |
| 2020 Q2 | 57.4 Million SEK | -0.83% |
| 2019 Q3 | 63.34 Million SEK | -8.62% |
| 2019 Q4 | 56.67 Million SEK | -10.53% |
| 2019 FY | 56.67 Million SEK | 72.9% |
| 2019 Q1 | 51.38 Million SEK | 56.75% |
| 2019 Q2 | 69.31 Million SEK | 34.9% |
| 2018 Q1 | 41.55 Million SEK | 4.34% |
| 2018 FY | 32.77 Million SEK | -17.69% |
| 2018 Q2 | 42.03 Million SEK | 1.15% |
| 2018 Q4 | 32.77 Million SEK | 34.09% |
| 2018 Q3 | 24.44 Million SEK | -41.84% |
| 2017 Q4 | 39.82 Million SEK | 30.4% |
| 2017 FY | 39.82 Million SEK | -13.17% |
| 2017 Q1 | 30.29 Million SEK | -33.93% |
| 2017 Q2 | 35.59 Million SEK | 17.49% |
| 2017 Q3 | 30.53 Million SEK | -14.21% |
| 2016 FY | 45.86 Million SEK | 83.5% |
| 2016 Q3 | 33.11 Million SEK | 9.23% |
| 2016 Q2 | 30.31 Million SEK | 6.94% |
| 2016 Q1 | 28.34 Million SEK | 13.42% |
| 2016 Q4 | 45.86 Million SEK | 38.5% |
| 2015 Q1 | 18.66 Million SEK | -13.92% |
| 2015 Q4 | 24.99 Million SEK | 33.69% |
| 2015 Q3 | 18.69 Million SEK | 2.48% |
| 2015 Q2 | 18.24 Million SEK | -2.25% |
| 2015 FY | 24.99 Million SEK | 15.28% |
| 2014 Q4 | 21.68 Million SEK | 8.69% |
| 2014 FY | 21.68 Million SEK | -33.15% |
| 2014 Q3 | 19.94 Million SEK | -29.0% |
| 2014 Q2 | 28.09 Million SEK | 16.42% |
| 2014 Q1 | 24.12 Million SEK | -25.6% |
| 2013 FY | 32.43 Million SEK | -52.94% |
| 2013 Q2 | 33.77 Million SEK | -39.72% |
| 2013 Q3 | 27.1 Million SEK | -19.76% |
| 2013 Q1 | 56.03 Million SEK | -18.7% |
| 2013 Q4 | 32.43 Million SEK | 19.65% |
| 2012 FY | 68.91 Million SEK | 1.64% |
| 2012 Q1 | 60.2 Million SEK | -11.21% |
| 2012 Q2 | 106.52 Million SEK | 76.94% |
| 2012 Q3 | 111.72 Million SEK | 4.88% |
| 2012 Q4 | 68.91 Million SEK | -38.31% |
| 2011 Q1 | 56.6 Million SEK | -11.33% |
| 2011 Q2 | 49 Million SEK | -13.43% |
| 2011 Q3 | 43.61 Million SEK | -10.99% |
| 2011 Q4 | 67.8 Million SEK | 55.45% |
| 2011 FY | 67.8 Million SEK | 6.21% |
| 2010 Q1 | 58.75 Million SEK | -16.79% |
| 2010 FY | 63.83 Million SEK | -9.59% |
| 2010 Q3 | 67.01 Million SEK | -10.79% |
| 2010 Q2 | 75.11 Million SEK | 27.84% |
| 2010 Q4 | 63.83 Million SEK | -4.74% |
| 2009 Q4 | 70.61 Million SEK | 0.0% |
| 2009 FY | 70.61 Million SEK | 10.11% |
| 2008 FY | 64.12 Million SEK | 12.74% |
| 2007 FY | 56.88 Million SEK | 48.99% |
| 2006 FY | 38.18 Million SEK | -19.36% |
| 2005 FY | 47.34 Million SEK | 84.02% |
| 2004 FY | 25.72 Million SEK | -32.7% |
| 2003 FY | 38.22 Million SEK | -26.71% |
| 2002 FY | 52.15 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 15.143% |
| Ziccum AB (publ) | 6.38 Million SEK | -1315.983% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -3734.379% |
| BioArctic AB (publ) | 139.5 Million SEK | 35.161% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -161.402% |
| Mendus AB (publ) | 51.22 Million SEK | -76.58% |
| Genovis AB (publ.) | 98.04 Million SEK | 7.745% |
| Intervacc AB (publ) | 21.68 Million SEK | -317.219% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -238.674% |
| Active Biotech AB (publ) | 13.4 Million SEK | -575.022% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 27.042% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -461.227% |
| Aptahem AB (publ) | 8.99 Million SEK | -905.276% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -121.378% |
| Kancera AB (publ) | 17.97 Million SEK | -403.132% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -95.871% |
| Fluicell AB (publ) | 8.91 Million SEK | -914.616% |
| Saniona AB (publ) | 86.08 Million SEK | -5.076% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1653.645% |
| Biovica International AB (publ) | 34.76 Million SEK | -160.169% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -675.223% |
| AcouSort AB (publ) | 10.37 Million SEK | -771.584% |
| Xintela AB (publ) | 14.01 Million SEK | -545.401% |
| Abliva AB (publ) | 16.78 Million SEK | -439.02% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 57.85% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -681.857% |
| OncoZenge AB (publ) | 1.69 Million SEK | -5223.896% |
| Amniotics AB (publ) | 10.54 Million SEK | -757.618% |
| 2cureX AB (publ) | 2.93 Million SEK | -2981.874% |
| CombiGene AB (publ) | 4.15 Million SEK | -2076.444% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1943.674% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 94.223% |
| Camurus AB (publ) | 414.81 Million SEK | 78.195% |
| Corline Biomedical AB | 6.78 Million SEK | -1232.346% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -47.421% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -371.994% |
| I-Tech AB | 16.2 Million SEK | -458.18% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 92.373% |
| Cyxone AB (publ) | 4.69 Million SEK | -1826.992% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -578.669% |
| Biosergen AB | 5.08 Million SEK | -1678.82% |
| Cantargia AB (publ) | 54.97 Million SEK | -64.55% |
| NextCell Pharma AB | 13.68 Million SEK | -560.769% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -25.891% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -556.809% |
| Nanologica AB (publ) | 79.32 Million SEK | -14.025% |
| SynAct Pharma AB | 51.83 Million SEK | -74.505% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -1037.917% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1641.174% |
| LIDDS AB (publ) | 3.75 Million SEK | -2308.227% |
| Lipum AB (publ) | 7.53 Million SEK | -1099.96% |
| Alzinova AB (publ) | 9.33 Million SEK | -869.382% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 50.191% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -4941.973% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -389.094% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -2256.774% |
| Simris Alg AB (publ) | 148.93 Million SEK | 39.268% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -27.187% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 81.241% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -609.769% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -1145.909% |